401 related articles for article (PubMed ID: 28684557)
1. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
[TBL] [Abstract][Full Text] [Related]
2. B cell biomarkers of rituximab responses in systemic lupus erythematosus.
Vital EM; Dass S; Buch MH; Henshaw K; Pease CT; Martin MF; Ponchel F; Rawstron AC; Emery P
Arthritis Rheum; 2011 Oct; 63(10):3038-47. PubMed ID: 21618204
[TBL] [Abstract][Full Text] [Related]
3. Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab.
Hassan SU; Md Yusof MY; Emery P; Dass S; Vital EM
Front Med (Lausanne); 2020; 7():498. PubMed ID: 32984378
[No Abstract] [Full Text] [Related]
4. Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.
Quelhas da Costa R; Aguirre-Alastuey ME; Isenberg DA; Saracino AM
JAMA Dermatol; 2018 Dec; 154(12):1432-1440. PubMed ID: 30383114
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Merrill JT; Neuwelt CM; Wallace DJ; Shanahan JC; Latinis KM; Oates JC; Utset TO; Gordon C; Isenberg DA; Hsieh HJ; Zhang D; Brunetta PG
Arthritis Rheum; 2010 Jan; 62(1):222-33. PubMed ID: 20039413
[TBL] [Abstract][Full Text] [Related]
6. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
7. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
Marinov AD; Wang H; Bastacky SI; van Puijenbroek E; Schindler T; Speziale D; Perro M; Klein C; Nickerson KM; Shlomchik MJ
Arthritis Rheumatol; 2021 May; 73(5):826-836. PubMed ID: 33277983
[TBL] [Abstract][Full Text] [Related]
8. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
[TBL] [Abstract][Full Text] [Related]
9. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
Reddy V; Jayne D; Close D; Isenberg D
Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
[TBL] [Abstract][Full Text] [Related]
10. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
[TBL] [Abstract][Full Text] [Related]
11. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.
Arnold J; Dass S; Twigg S; Jones CH; Rhodes B; Hewins P; Chakravorty M; Courtney P; Ehrenstein M; Md Yusof MY; Vital EM
Rheumatology (Oxford); 2022 Nov; 61(12):4905-4909. PubMed ID: 35266512
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
Tanaka Y; Yamamoto K; Takeuchi T; Nishimoto N; Miyasaka N; Sumida T; Shima Y; Takada K; Matsumoto I; Saito K; Koike T
Mod Rheumatol; 2007; 17(3):191-7. PubMed ID: 17564773
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
[TBL] [Abstract][Full Text] [Related]
15. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
16. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
17. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
18. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
[TBL] [Abstract][Full Text] [Related]
20. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.
Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Ann Rheum Dis; 2007 Sep; 66(9):1259-62. PubMed ID: 17412738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]